{"id":9331,"date":"2025-12-09T14:15:19","date_gmt":"2025-12-09T11:15:19","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9331"},"modified":"2025-12-09T14:15:19","modified_gmt":"2025-12-09T11:15:19","slug":"esaxerenone-sglt2i-in-hypertensive-t2dm-patients","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/esaxerenone-sglt2i-in-hypertensive-t2dm-patients\/","title":{"rendered":"Esaxerenone +\/\u2013 SGLT2i in Hypertensive T2DM Patients"},"content":{"rendered":"<div>Esaxerenone +\/\u2013 SGLT2i in Hypertensive T2DM Patients<\/div>\n<div><\/div>\n<div>Source: Hypertension News \u2013 International Society of Hypertension, December 2025<\/div>\n<div><\/div>\n<div>Keynotes :<\/div>\n<div><span> \u2022 Study type: pooled analysis of 5 prospective clinical studies (\u2248280 patients).<\/span><\/div>\n<div><span> \u2022 Drug: Esaxerenone \u2014 a nonsteroidal mineralocorticoid receptor blocker (MRB).<\/span><\/div>\n<div><span> \u2022 Population: Hypertensive patients with type 2 diabetes \u2014 with and without SGLT2 inhibitor therapy.<\/span><\/div>\n<div><\/div>\n<div>1.\u2060 \u2060Blood Pressure Reduction<\/div>\n<div><span> \u2022 Significant BP drop by week 12 in all groups.<\/span><\/div>\n<div><span> \u2022 Overall: \u221211.9 \/ \u22125.2 mmHg<\/span><\/div>\n<div><span> \u2022 With SGLT2i: \u221211.3 \/ \u22124.8 mmHg<\/span><\/div>\n<div><span> \u2022 Without SGLT2i: \u221212.5 \/ \u22125.7 mmHg<\/span><\/div>\n<div><span> \u2022 ~70% achieved home BP target &lt;135\/85 mmHg.<\/span><\/div>\n<div><\/div>\n<div>2.\u2060 \u2060Kidney &amp; Cardiac Effects<\/div>\n<div><span> \u2022 Albuminuria (UACR) improved by ~43% in all groups.<\/span><\/div>\n<div><span> \u2022 NT-proBNP improved regardless of SGLT2i use.<\/span><\/div>\n<div><\/div>\n<div>3.\u2060 \u2060Safety<\/div>\n<div><span> \u2022 Mild rise in serum potassium at week 2 \u2192 stabilized by week 12.<\/span><\/div>\n<div><span> \u2022 Hyperkalemia \u22655.5 mEq\/L:<\/span><\/div>\n<div><span> \u2022 2.0% with SGLT2i<\/span><\/div>\n<div><span> \u2022 5.2% without SGLT2i<\/span><\/div>\n<div>\u2192 SGLT2 inhibitors may reduce hyperkalemia risk.<\/div>\n<div><\/div>\n<div>4.\u2060 \u2060Clinical Interpretation<\/div>\n<div><span> \u2022 Esaxerenone is effective with or without SGLT2 inhibitors.<\/span><\/div>\n<div><span> \u2022 Combined use appears safe with complementary mechanisms (natriuresis + MR blockade).<\/span><\/div>\n<div><span> \u2022 Esaxerenone preferred over finerenone when both hypertension control and albuminuria reduction are needed.<\/span><\/div>\n<div><\/div>\n<div>Bottom Line<\/div>\n<div><\/div>\n<div>Esaxerenone provides strong BP lowering, improves albuminuria and cardiac markers, and maintains a favorable safety profile\u2014showing even lower potassium risk when combined with SGLT2 inhibitors.<\/div>\n<div>\ud83d\udd17 Full Article:<a href=\"https:\/\/ish-world.com\/document\/1764854170.pdf\"> https:\/\/ish-world.com\/document\/1764854170.pdf<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Esaxerenone +\/\u2013 SGLT2i in Hypertensive T2DM Patients Source: Hypertension News \u2013 International Society of Hypertension, December 2025 Keynotes : \u2022 Study type: pooled analysis of 5 prospective clinical studies (\u2248280 patients). \u2022 Drug: Esaxerenone \u2014 a nonsteroidal mineralocorticoid receptor blocker (MRB). \u2022 Population: Hypertensive patients with type 2 diabetes \u2014 with and without SGLT2 inhibitor [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9331","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9331"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9331\/revisions"}],"predecessor-version":[{"id":9332,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9331\/revisions\/9332"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}